Table 5 Drug Resistance Among 559 Participants with MDR-TB, by Prior Drug of interest and MDR-TB Treatment Status
From: Few eligible for the newly recommended short course MDR-TB regimen at a large Mumbai private clinic
Drug | Received Any Prior MDR-TB Treatment, N = 267a | Received No Prior MDR-TB Treatment, N = 289a | All Participants, N = 559a | Χ2 Test |
|---|---|---|---|---|
# Resistant / # Tested (%)b | # Resistant / # Tested (%)b | # Resistant / # Tested (%)b | p-value | |
Isoniazid | 246 / 248 (99.2) | 217 / 219 (99.1) | 465 / 469 (99.1) | 1.000 |
Rifampin | 289 / 289 (100) | 267 / 267 (100) | 559 / 559 (100) | 1.000 |
Pyrazinamide | 185 / 228 (81.1) | 176 / 213 (82.6) | 363 / 443 (81.9) | 0.778 |
Ethambutol | 212 / 237 (89.5) | 178 / 219 (81.3) | 392 / 458 (85.6) | 0.019 |
Streptomycin | 167 / 177 (94.4) | 91 / 100 (91.0) | 260 / 279 (93.2) | 0.417 |
Ofloxacin | 183 / 233 (78.5) | 141 / 211 (66.8) | 326 / 446 (73.1) | 0.008 |
Moxifloxacin (low) | 157 / 229 (68.6) | 122 / 208 (58.7) | 281 / 439 (64.0) | 0.040 |
Moxifloxacin (high) | 34 / 145 (23.4) | 30 / 178 (16.9) | 65 / 324 (20.1) | 0.181 |
Kanamycin | 73 / 244 (29.9) | 35 / 217 (16.1) | 110 / 463 (23.8) | < 0.001 |
Amikacin | 51 / 225 (22.7) | 23 / 206 (11.2) | 76 / 433 (17.6) | 0.002 |
Capreomycin | 48 / 235 (20.4) | 22 / 212 (10.4) | 72 / 449 (16.0) | 0.005 |
Ethionamide | 150 / 231 (64.9) | 122 / 218 (56.0) | 274 / 451 (60.8) | 0.065 |
PAS | 72 / 231 (31.2) | 28 / 217 (12.9) | 101 / 450 (22.4) | < 0.001 |
Clofazimine | 8 / 219 (3.7) | 3 / 204 (1.5) | 11 / 425 (2.6) | 0.270 |
Linezolid | 13 / 136 (9.6) | 6 / 171 (3.5) | 20 / 308 (6.5) | 0.052 |